205.72
0.53%
-1.53
Beigene Ltd Adr stock is traded at $205.72, with a volume of 135.61K.
It is down -0.53% in the last 24 hours and down -16.21% over the past month.
BeiGene Ltd is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. BeiGene's key cancer treatments are BRUKINSA (zanubrutinib), Bruton's tyrosine kinase (BTK) inhibitor, and TEVIMBRA (tislelizumab), an anti-PD-1 antibody. In addition, it has a diverse pipeline of novel therapeutics focusing on a range of malignancies, including AML, MDS, multiple myeloma, lung, gastrointestinal, breast, and gynecologic cancers. The Company operates in one segment: pharmaceutical products and is primarily located in the U.S. and the PRC. Key revenue is generated from the U.S.
See More
Previous Close:
$207.25
Open:
$208.13
24h Volume:
135.61K
Relative Volume:
0.42
Market Cap:
$22.04B
Revenue:
$3.10B
Net Income/Loss:
$-523.70M
P/E Ratio:
-12.32
EPS:
-16.6978
Net Cash Flow:
$-1.36B
1W Performance:
-4.79%
1M Performance:
-16.21%
6M Performance:
+27.06%
1Y Performance:
+12.17%
Beigene Ltd Adr Stock (BGNE) Company Profile
Name
Beigene Ltd Adr
Sector
Industry
Phone
13459494123
Address
C/O MOURANT GOVERNANCE SERVICES (CAYMAN), GRAND CAYMAN
Beigene Ltd Adr Stock (BGNE) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-06-24 | Resumed | JP Morgan | Overweight |
Sep-12-23 | Initiated | Macquarie | Outperform |
Aug-17-23 | Initiated | Jefferies | Buy |
Jul-17-23 | Initiated | Citigroup | Buy |
Jun-30-23 | Downgrade | Bernstein | Outperform → Mkt Perform |
Jan-12-23 | Initiated | Daiwa Securities | Buy |
Oct-13-22 | Upgrade | Guggenheim | Neutral → Buy |
Oct-13-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
Aug-09-22 | Resumed | JP Morgan | Overweight |
Mar-17-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
Feb-07-22 | Initiated | Deutsche Bank | Buy |
Oct-12-21 | Initiated | Bernstein | Outperform |
Oct-06-21 | Upgrade | CLSA | Underperform → Buy |
Mar-08-21 | Initiated | China Renaissance | Buy |
Mar-01-21 | Downgrade | CLSA | Outperform → Underperform |
Nov-09-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
Nov-06-20 | Downgrade | Maxim Group | Buy → Hold |
Nov-06-20 | Downgrade | Piper Sandler | Neutral → Underweight |
Jul-10-20 | Downgrade | CLSA | Buy → Outperform |
Mar-13-20 | Upgrade | Macquarie | Underperform → Neutral |
Feb-18-20 | Resumed | Goldman | Buy |
Jan-17-20 | Upgrade | CLSA | Outperform → Buy |
Jan-17-20 | Resumed | Morgan Stanley | Overweight |
Dec-16-19 | Downgrade | Guggenheim | Buy → Neutral |
Dec-16-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
Nov-19-19 | Downgrade | UBS | Buy → Neutral |
Nov-13-19 | Downgrade | CLSA | Buy → Outperform |
Nov-04-19 | Reiterated | Maxim Group | Buy |
Jun-04-19 | Initiated | Bernstein | Outperform |
May-10-19 | Upgrade | CLSA | Outperform → Buy |
Mar-15-19 | Initiated | BofA/Merrill | Buy |
Jan-04-19 | Downgrade | CLSA | Buy → Outperform |
Nov-21-18 | Initiated | JP Morgan | Overweight |
Sep-25-18 | Initiated | Leerink Partners | Outperform |
May-17-18 | Reiterated | Maxim Group | Buy |
View All
Beigene Ltd Adr Stock (BGNE) Latest News
Zymeworks Announces Participation in Upcoming Investor Conferences - GlobeNewswire Inc.
BeiGene announces passing of board member Donald Glazer - Investing.com
BEIGENE Senior Staff Reportedly Investigated, but Not Related to Firm Operations - AASTOCKS.com
Indaptus Therapeutics partners with BeiGene for cancer study - Investing.com India
BeiGene stock momentum builds on Brukinsa success, says JPMorgan's Fye - Investing.com
CMBI Eyes Opportunities in Innovative Medical Insurance, Prefers WuXi AppTec/ BeiGene/ INNOVENT BIO/ SKB BIO-B/ GIANT BIOGENE/ 3SBIO/ Mindray Bio-MedicalUS StocksGlobal News Content - AASTOCKS.com
Financial Fitness Check: Examining BeiGene Ltd ADR (BGNE)’s Key Ratios - The Dwinnex
The Potential Rise in the Price of BeiGene Ltd ADR (BGNE) following insiders activity - Knox Daily
Samsara Inc (IOT) may enjoy gains as insiders got busy in the recent days - Knox Daily
Monitoring Ginkgo Bioworks Holdings Inc (DNA) after recent insider movements - Knox Daily
Insider Sale Alert: PepsiCo Inc [PEP] – Is it Time to sell? - Knox Daily
VZIO (VIZIO Holding Corp) may reap gains as insiders became active recently - Knox Daily
Investing in Allegro Microsystems Inc. (ALGM) Is Getting More Attractive - Knox Daily
Investing in Alphatec Holdings Inc (ATEC): What You Must Know - Knox Daily
An Analysis of Mercury Systems Inc (MRCY)’s Potential Price Growth - Knox Daily
XPeng Inc. Sponsored ADR (XPEV) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance
BeiGene CEO John Oyler sells shares worth over $3.75 million - Investing.com
Royal Caribbean Group [RCL] Shares Rise 5.26 % on Wednesday - Knox Daily
Selling Buzz: UL Solutions Inc [ULS] 10% Owner ULSE Inc. sells 3,000,000 shares of the company - Knox Daily
Director Cui Xiangmin acquire 277,895 shares of Nuvation Bio Inc [NUVB] - Knox Daily
Taking a look at what insiders are doing to gauge the BeiGene Ltd ADR (BGNE)’s direction - Knox Daily
Stock Performance Spotlight: BeiGene Ltd ADR (BGNE) Ends the Day at 240.40, Up by 2.11 - The Dwinnex
Buying Buzz: Vuzix Corporation [VUZI] Director Harned Timothy Heydenreich purchases 20,000 shares of the company - Knox Daily
A company insider recently sold 1,447 shares of uniQure N.V. [QURE]. Should You Sale? - Knox Daily
Director Stark Eugene S acquire 2,500 shares of Prospect Capital Corp [PSEC] - Knox Daily
It makes sense and dollars to buy BeiGene Ltd ADR (BGNE) stock - SETE News
Recent Insider Activity Could Benefit ACI Worldwide Inc (ACIW) - Knox Daily
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)? - Yahoo Finance
A company insider recently sold 7,662 shares of S&P Global Inc [SPGI]. Should You Sale? - Knox Daily
BeiGene's SVP sells shares worth nearly $285k - Investing.com
BeiGene's SVP sells shares worth nearly $285k By Investing.com - Investing.com UK
BeiGene executive sells over $1.1m in company shares By Investing.com - Investing.com South Africa
BeiGene executive sells over $1.1m in company shares - Investing.com India
BeiGene stock soars to 52-week high, touches $220 mark - Investing.com
A company insider recently sold 24 shares of Phreesia Inc [PHR]. Should You Sale? - Knox Daily
BeiGene adds new board member with financial expertise - Investing.com
BeiGene executive Wu Xiaobin sells over $1 million in company stock - Investing.com India
BeiGene (NASDAQ:BGNE) Now Covered by Analysts at JMP Securities - Defense World
JMP calls BeiGene a 'unique investment opportunity', sets $288 shares target By Investing.com - Investing.com
New additions to Roth MKM’s ADR portfolio for September - MSN
Opera Limited Sponsored ADR (OPRA) Crossed Above the 20-Day Moving Average: What That Means for Investors - Yahoo Finance
Checking in on BeiGene Ltd ADR (BGNE) after recent insiders movement - Knox Daily
BeiGene stock touches 52-week high at $211.56 amid market fluctuations - Investing.com
Analyzing Jefferies Financial Group Inc (JEF) After Recent Trading Activity - Knox Daily
VICI Properties Inc [VICI] stock for 201,530 USD was bought by ABRAHAMSON JAMES R - Knox Daily
BeiGene executive sells $26,021 in company stock - Investing.com India
BeiGene exec Wu Xiaobin sells over $1m in company shares - Investing.com
Are Smart Investors Making the Right Decision? BeiGene Ltd ADR (BGNE) - SETE News
Imperial Capital’s latest rating for GSAT stock - Knox Daily
Wells Fargo initates MSCI Inc (MSCI) rating to an Equal weight - Knox Daily
MAIA Biotechnology Inc [MAIA] Investment Guide: What You Need to Know - Knox Daily
Beigene Ltd Adr Stock (BGNE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):